Table 1 Summary of patients and samples included in the longitudinal cohort
From: Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
Biomarker quantification method | Number of DMD patients | Number of samples | ||||
|---|---|---|---|---|---|---|
Total | 3 time-points | 4 time-points | 5 time-points | DMD patients | Controls | |
PRM-MS | 20 | 11 | 6 | 3 | 72 | 12 |
Sandwich immuno-assay | 20 | 12 | 5 | 3 | 71* | 12 |